BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$314.94 USD
+4.91 (1.58%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $315.00 +0.06 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum D VGM
- YR Estimate
- 12/31/2023
- 12/31/2022
- 12/31/2021
- 12/31/2020
- 12/31/2019
- Revenue - Line of Business (LOBR)
- Net sales: Life Science
- 1,178.40
- 1,347.20
- 1,400.80
- 1,231.80
- 885.90
- Revenue - Line of Business (LOBR)
- Net sales: Clinical Diagnostics
- 1,489.30
- 1,451.00
- 1,515.90
- 1,305.20
- 1,412.00
- Revenue - Line of Business (LOBR)
- Net sales: Other Operations
- 3.60
- 4.00
- 5.80
- 8.60
- 13.80
- Revenue - Geographic (GEOR)
- Geographic Revenue: United States
- 1,121.90
- 1,155.50
- 1,130.60
- 1,004.80
- 899.10
- Revenue - Geographic (GEOR)
- Geographic Revenue: EMEA
- 819.80
- 851.90
- 946.90
- 857.70
- 770.30
- Revenue - Geographic (GEOR)
- Geographic Revenue: Asia
- 563.00
- 639.40
- 688.40
- 546.50
- 505.00
- Revenue - Geographic (GEOR)
- Geographic Revenue: Other (primarily Canada and Latin America)
- 166.60
- 155.40
- 156.60
- 136.60
- 137.30
- Income - Line of Business (LOBI)
- Segment profit (loss): Life science
- 108.90
- --
- 316.00
- 271.80
- 72.10
- Income - Line of Business (LOBI)
- Segment profit (loss): Clinical Diagnostics
- 229.60
- --
- 173.00
- 117.00
- 148.50
- Income - Line of Business (LOBI)
- Segment profit (loss): Other Operations
- -0.70
- --
- -1.10
- 0.30
- -1.50